| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
Purity: ≥98%
Tigilanol tiglate, formerly known as EBC-46, is a naturally occuring phorbol ester and an experimental anticancer drug candidate being studied pre-clinically. It was discovered through an automated screening process of natural products by selecting increasingly purified fractions of plant extracts, based on their ability to produce the desired activity profile. This is then followed by artificial synthesis of the isolated compound to confirm its chemical structure. Along with other related compounds, it acts as a protein kinase C regulator.
| References |
: Boyle GM, D'Souza MM, Pierce CJ, Adams RA, Cantor AS, Johns JP, Maslovskaya L, Gordon VA, Reddell PW, Parsons PG. Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models. PLoS One. 2014 Oct 1;9(10):e108887. doi: 10.1371/journal.pone.0108887. eCollection 2014. PubMed PMID: 25272271; PubMed Central PMCID: PMC4182759.
|
|---|---|
| Additional Infomation |
Tigilanol tiglate is a diterpenoid natural product isolated from the seeds of the Australian redwood tree (Fontainea picrosperma). It has been approved as a veterinary drug for the treatment of non-metastatic and unresectable canine mast cell tumors. It possesses antitumor activity and is a plant metabolite and protein kinase C agonist. It is a diterpenoid compound, phorbol ester, diester, and organic heteropentane compound. Tigilanol tiglate is a short-chain diterpenoid ester isolated from the seeds of the Australian redwood tree with potential antitumor activity. Upon intratumoral injection, tigilanol tiglate disrupts mitochondrial function and induces mitochondrial swelling, leading to the lysis of tumor cells in direct contact with the drug. Furthermore, tigilanol tiglate activates the protein kinase C (PKC) signaling cascade, triggering an acute inflammatory response. This leads to hypoxia and activates innate immune cells, including neutrophils and macrophages, further killing tumor cells. Activation of the PKC β-II subtype (PKC β II) also increases tumor vascular permeability, leading to tumor vascular destruction.
Drug Indications For the treatment of unresectable, non-metastatic (WHO staging) subcutaneous mast cell tumors of the elbow or tarsal joint and distal parts of the dog, as well as unresectable, non-metastatic cutaneous mast cell tumors. |
| Molecular Formula |
C30H42O10
|
|---|---|
| Molecular Weight |
562.66
|
| Exact Mass |
562.277
|
| CAS # |
943001-56-7
|
| Related CAS # |
943001-56-7
|
| PubChem CID |
92135637
|
| Appearance |
White to off-white solid powder
|
| Density |
1.35±0.1 g/cm3(Predicted)
|
| Boiling Point |
682.1±55.0 °C(Predicted)
|
| LogP |
2.1
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
40
|
| Complexity |
1220
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CC[C@H](C)C(=O)O[C@@]12[C@@H](C1(C)C)[C@@H]3[C@H]4[C@](O4)([C@H]([C@]5([C@H]([C@]3([C@@H]([C@H]2OC(=O)/C(=C/C)/C)C)O)C=C(C5=O)C)O)O)CO
|
| InChi Key |
YLQZMOUMDYVSQR-RMNSOQACSA-N
|
| InChi Code |
InChI=1S/C30H42O10/c1-9-13(3)23(33)38-21-16(6)28(36)17-11-15(5)20(32)29(17,37)25(35)27(12-31)22(39-27)18(28)19-26(7,8)30(19,21)40-24(34)14(4)10-2/h9,11,14,16-19,21-22,25,31,35-37H,10,12H2,1-8H3/b13-9+/t14?,16-,17?,18?,19?,21-,22+,25-,27+,28+,29-,30-/m1/s1
|
| Chemical Name |
(1cS,2aR,3S,3aS,6bR,7R,8R,8aS)-3,3a,6b-trihydroxy-2a-(hydroxymethyl)-1,1,5,7-tetramethyl-8a-((2-methylbutanoyl)oxy)-4-oxo-1a,1b,1c,2a,3,3a,4,6a,6b,7,8,8a-dodecahydro-1H-cyclopropa[5',6']benzo[1',2'
|
| Synonyms |
Tigilanol tiglate EBC-46 EBC46 EBC 46
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7773 mL | 8.8864 mL | 17.7727 mL | |
| 5 mM | 0.3555 mL | 1.7773 mL | 3.5545 mL | |
| 10 mM | 0.1777 mL | 0.8886 mL | 1.7773 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA